Sionna Therapeutics, Inc
Price
FilingsNewest: 8-K, Exit or restructuring costsSep 14 →InsidersNo open-market buys. 15 insiders sold $148.0M, 85 of 130 sales on a 10b5-1 plan.→HoldersRa 21.9%TPG GP A 14.4%Viking Global Investors 7.1%→Financing →PeersClosest companies: CGEM, CCCC, BDTX→
From the filings
Figures
- Net income
- −$97.4Mlast 12 months
- Operating cash flow
- −$71.8Mlast 12 months
- Cash and equivalents
- $63.3Mat the last balance sheet
- Shares outstanding
- 45.2M shareson issue